12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Company News  |  Deals

ImmunoCellular, University of Pittsburgh deal

The university granted ImmunoCellular rights to IP related to EPH receptor A2 (EPHA2), a tyrosine kinase receptor. ImmunoCellular will have an exclusive, worldwide license to use the IP...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >